Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson's disease in the MPTP-induced mice model

Journal of Drug Targeting

Volumn 20, Issue 1, 2012, Pages 67-75

  Xiang, Y ^a   Wu, Qian ^a   Liang, Liang ^a   Wang, Xueqing ^a   Wang, Jiancheng ^a   Zhang, Xuan ^a   Pu, Xiaoping ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Chlorotoxin; Levodopa; Liposomes; Parkinson's disease; Targeted drug delivery

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETIC ACID; CHLOROTOXIN; DIHYDROXYPHENYL ACETIC ACID; DOPAMINE; DOXORUBICIN; LEVODOPA; LIPOSOME; TOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG IDENTIFICATION; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSPORT; ENCAPSULATION; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; LEVODOPA; LIPOSOMES; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; PARKINSON DISEASE; RANDOM ALLOCATION; SCORPION VENOMS;

EID: 83155164543     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.595490     Document Type: Article

References (42)

1. Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y. (2001). Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- treated mouse. Eur J Pharm Sci, 12, 231-238.
2. Black KJ, Carl JL, Hartlein JM, Warren SL, Hershey T, Perlmutter JS. (2003). Rapid intravenous loading of levodopa for human research: Clinical results. J Neurosci Methods, 127, 19-29. (Pubitemid 36809231)
3. Bigotte L. (1985). Doxorubicin as a fluorescent nuclear marker in tumors of the human nervous system: A simple and reliable staining technique. Clin Neuropathol, 4, 220-226. (Pubitemid 16250183)
4. Dai W, Yang T, Wang X, Wang J, Zhang X, Zhang Q. (2010). PHSCNKModified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells. J Drug Target, 18, 254-263.
5. Dai X, Yue Z, Eccleston ME, Swartling J, Slater NK, Kaminski CF. (2008). Fluorescence intensity and lifetime imaging of free and micellar-encapsulated doxorubicin in living cells. Nanomedicine, 4, 49-56.
6. DeBin JA, Strichartz GR. (1991). Chloride channel inhibition by the venom of the scorpion Leiurus quinquestriatus. Toxicon, 29, 1403-1408.
7. De Boer AG, Gaillard PJ. (2007). Drug targeting to the brain. Annu Rev Pharmacol Toxicol, 47, 323-355.
8. Di Stefano A, Carafa M, Sozio P, Pinnen F, Braghiroli D, Orlando G, Cannazza G, Ricciutelli M, Marianecci C, Santucci E. (2004). Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations. J Control Release, 99, 293-300. (Pubitemid 39222114)
9. Di Stefano A, Sozio P, Iannitelli A, Marianecci C, Santucci E, Carafa M. (2006). Maleic- and fumaric-diamides of (O,O-diacetyl)-L-dopamethylester as anti-Parkinson prodrugs in liposomal formulation. J Drug Target, 14, 652-661. (Pubitemid 44712361)
10. Düzgüne&scedil N, Nir S. (1999). Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev, 40, 3-18. (Pubitemid 29486601)
11. Fahn S, Przedborski S. (2005). Parkinsonism. In: Rowland LP, ed. Merritts Neurology, 10th ed. Philadelphia: Lippincott Williams &Wilkins, pp. 828-846.
12. Fahn S. (2006). Levodopa in the treatment of Parkinsons disease. J Neural Transm Suppl, 71, 1-15.
13. Goole J, Amighi K. (2009). Levodopa delivery systems for the treatment of Parkinsons disease: An overview. Int J Pharm, 380, 1-15.
14. Haran G, Cohen R, Bar LK, Barenholz Y. (1993). Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta, 1151, 201-215. (Pubitemid 23283973)
15. Jacoby DB, Dyskin E, Yalcin M, Kesavan K, Dahlberg W, Ratliff J, Johnson EW, Mousa SA. (2010). Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide. Anticancer Res, 30, 39-46.
16. Jankovic J. (2002). Levodopa strengths and weaknesses. Neurology, 58, S19-S32. (Pubitemid 34163497)
17. Kachra Z, Beaulieu E, Delbecchi L, Mousseau N, Berthelet F, Moumdjian R, Del Maestro R, Béliveau R. (1999). Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis, 17, 555-566. (Pubitemid 30337129)
18. Kesavan K, Ratliff J, Johnson EW, Dahlberg W, Asara JM, Misra P, Frangioni JV, Jacoby DB. (2010). Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem, 285, 4366-4374.
19. Kopin IJ, Markey SP. (1988). MPTP toxicity: Implications for research in Parkinsons disease. Annu Rev Neurosci, 11, 81-96. (Pubitemid 18081034)
20. Lach B, Grimes D, Benoit B, Minkiewicz-Janda A. (1992). Caudate nucleus pathology in Parkinsons disease: Ultrastructural and biochemical findings in biopsy material. Acta Neuropathol, 83, 352-360.
21. Leng A, Mura A, Hengerer B, Feldon J, Ferger B. (2004). Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice. Behav Brain Res, 154, 375-383. (Pubitemid 39093988)
22. Lou J, Gasche Y, Zheng L, Critico B, Monso-Hinard C, Juillard P, Morel P, Buurman WA, Grau GE. (1998). Differential reactivity of brain microvascular endothelial cells to TNF reflects the genetic susceptibility to cerebral malaria. Eur J Immunol, 28, 3989-4000. (Pubitemid 28558629)
23. Lyons SA, ONeal J, Sontheimer H. (2002). Chlorotoxin, a scorpionderived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia, 39, 162-173. (Pubitemid 34817056)
24. Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, Levey AI. (1997). Immunochemical analysis of dopamine transporter protein in Parkinsons disease. Ann Neurol, 41, 530-539. (Pubitemid 27169193)
25. Nagatsu T, Sawada M. (2009). L-dopa therapy for Parkinsons disease: Past, present, and future. Parkinsonism Relat Disord, 15 (Suppl. 1), S3-S8.
26. Nowacek A, Kosloski LM, Gendelman HE. (2009). Neurodegenerative disorders and nanoformulated drug development. Nanomedicine (Lond), 4, 541-555.
27. Oertel WH, Ellgring H. (1995). Parkinsons disease-medical education and psychosocial aspects. Patient Educ Couns, 26, 71-79.
28. Pardridge WM. (2002). Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov, 1, 131-139. (Pubitemid 41646520)
29. Pardridge WM. (2007a). Blood-brain barrier delivery. Drug Discov Today, 12, 54-61. (Pubitemid 46014479)
30. Pardridge WM. (2007b). Drug targeting to the brain. Pharm Res, 24, 1733-1744. (Pubitemid 47206623)
31. Rozas G, López-Martín E, Guerra MJ, Labandeira- García JL. (1998). The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods, 83, 165-175. (Pubitemid 28442608)
32. Samad A, Sultana Y, Aqil M. (2007). Liposomal drug delivery systems: An update review. Curr Drug Deliv, 4, 297-305. (Pubitemid 47554274)
33. Schmidt N, Ferger B. (2001). Neurochemical findings in the MPTP model of Parkinsons disease. J Neural Transm, 108, 1263-1282. (Pubitemid 33141302)
34. Shastry BS. (2001). Parkinson disease: Etiology, pathogenesis and future of gene therapy. Neurosci Res, 41, 5-12. (Pubitemid 32776631)
35. Sommer B, Barbieri S, Hofele K, Wiederhold K, Probst A, Mistl C, Danner S, Kauffmann S, Spooren W, Tolnay M, Bilbe G, van der Putten H, Kafmann S, Caromi P, Ruegg MA. (2000). Mouse models of alphasynucleinopathy and Lewy pathology. Exp Gerontol, 35, 1389-1403.
36. Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, Ravanpay AC, Stroud MR, Kusuma Y, Hansen SJ, Kwok D, Munoz NM, Sze RW, Grady WM, Greenberg NM, Ellenbogen RG, Olson JM. (2007). Tumor paint: A chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res, 67, 6882-6888. (Pubitemid 47105535)
37. Veiseh O, Sun C, Fang C, Bhattarai N, Gunn J, Kievit F, Du K, Pullar B, Lee D, Ellenbogen RG, Olson J, Zhang M. (2009). Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res, 69, 6200-6207.
38. Watanabe H, Muramatsu Y, Kurosaki R, Michimata M, Matsubara M, Imai Y, Araki T. (2004). Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: An immunohistological study. Eur Neuropsychopharmacol, 14, 93-104. (Pubitemid 38175426)
39. Xiong XB, Huang Y, Lu WL, Zhang H, Zhang X, Zhang Q. (2005). Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res, 22, 933-939. (Pubitemid 40898103)
40. Xu YG, Pang XF, Gi JJ. (2006). The evaluation and method on several typical MPTP-induced mouse PD models. Prog Biochem Biophys, 33, 1014-1018.
41. Yang ZD, Zhang X, Guo H, Gan Y. (2006). Simultaneous determination of monoamines, their precursor amino acids and related metabolites in mice brain by high-performance liquid chromatography with a coulometric electrode array system. Anal Lett, 39, 1837-1851. (Pubitemid 43982305)
42. Zhang J, Jin W, Wang X, Wang J, Zhang X, Zhang Q. (2010). A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharm, 7, 1159-1168.